Regencell Bioscience Holdings annual return on equity
2022
2023
2024
2025
Regencell Bioscience Holdings Return on Equity (ROE) Growth & History (RGC)
Regencell Bioscience Holdings's return on equity was −54.81% for fiscal 2025.
View full Regencell Bioscience Holdings company overviewRegencell Bioscience Holdings annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-06-30 | −54.81% | −12.32 pp |
| 2024 | 2024-06-30 | −42.49% | −2.13 pp |
| 2023 | 2023-06-30 | −40.36% | +73.60 pp |
| 2022 | 2022-06-30 | −113.96% | — |
Regencell Bioscience Holdings return on equity trends
Between the periods ended 2022-06-30 and 2025-06-30, Regencell Bioscience Holdings's return on equity increased from −113.96% to −54.81%, a change of +59.15 percentage points.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Regencell Bioscience Holdings source filings ↗